About Alector
Alector is a clinical-stage biopharmaceutical company developing therapies to counteract the progression of neurodegeneration. The company focuses on neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia, and Parkinson's disease, leveraging insights from immunology, neuroscience, and human genetics. Its pipeline includes antibody-based programs and a proprietary Alector Brain Carrier (ABC) platform designed to improve therapeutic delivery across the blood-brain barrier.
Company details
Funding
Total raised
$215M
Last stage
Public
Investors
Founders
Arnon Rosenthal
PhD from Hebrew University of Jerusalem; previously Executive Researcher at Genentech for 16 years; Co-Founder, CSO & President of Rinat Neurosciences (acquired by Pfizer in 2006).
LinkedInAsa Abeliovich
MD/PhD; formerly Associate Professor at the Taub Institute for the Aging Brain at Columbia University and Neurologist. Also co-founded Leal Therapeutics and Prevail Therapeutics.
Tillman Gerngross
Professor of Bioengineering at Dartmouth College; Co-Founder & CEO of Adimab; Co-Founder & CSO of GlycoFi (acquired by Merck in 2006).
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.